Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3138 - The clinical utility of early follow-up computed tomography in patients with stage II-III colorectal cancer receiving oxaliplatin-based chemotherapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Staging and Imaging

Tumour Site

Colon and Rectal Cancer

Presenters

Yongjune Lee

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Y. Lee, S.Y. Kim, J.E. Kim, Y.S. Hong, T.W. Kim

Author affiliations

  • Department Of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
More

Resources

Abstract 3138

Background

Surveillance after curative resection for colorectal cancer with computed tomography (CT) of abdomen, pelvis and chest is a standard practice, but the optimal interval of surveillance CT is unclear. Usually recommended interval is 6 to 12 months, but in South Korea, earlier follow-up CT during adjuvant chemotherapy for stage II or III disease is a common practice. This study aimed to show clinical utility of early follow-up CT (EFCT) within 6 months after surgery.

Methods

The medical records of patients with stage II or III colorectal cancer who received oxaliplatin-based adjuvant chemotherapy between January 2011 and December 2014 in Asan Medical Center were retrospectively reviewed. Those who started adjuvant chemotherapy beyond 3 months after surgery and who were dead or lost to follow-up before 6 months after surgery were excluded. Information on the results of EFCT and subsequent treatment was obtained.

Results

In a total of 678 patients, 597 (88%) underwent EFCT. EFCT was associated with advanced stage: 78% (74/95) of stage II, 88% (317/359) of low-risk stage III (pT1-3 and N1), and 92% (206/224) of high-risk stage III (pT4 or N2) checked EFCT (p = 0.002). EFCT revealed recurrence in 6 (1%); 0 of stage II, 1 (0.3%) of low-risk stage III, and 5 (2.4%) of high-risk stage III (p = 0.132). Only 1 of 6 patients with recurrence underwent surgical resection of curative intent. There were no differences in overall survival (OS), disease-free survival (DFS), and cumulative occurrence of local treatment for DFS events according to undergoing EFCT with adjustment to age, gender, and stage.

Conclusions

Early recurrence within 6 months after surgery occurred in 1% of patients who were treated with oxaliplatin-based adjuvant chemotherapy, mostly in high-risk stage III disease. The practice of EFCT was associated with advanced stage but did not affect OS, DFS, or cumulative occurrence of local treatment. Clinical utility of EFCT seems to be low and should be discouraged especially in stage II or low-risk stage III disease.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.